Latest News and Press Releases

Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.

Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.

Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.

Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.

Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.

Myriad Genetics announced Prequel® Prenatal Screen is now available at eight weeks into pregnancy.

Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations.

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third...

Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing